BACKGROUND: The purpose of this study was to determine whether the use of optimized CT treatment planning offered better coverage of axillary level III (LIII)/supraclavicular (SC) targets than the empirically derived dose prescription that are commonly used. MATERIALS/ METHODS: Thirty-two consecutive breast cancer patients who underwent CT treatment planning of a SC field were evaluated. Each patient was categorized according to body mass index (BMI) classes: normal, overweight, or obese. The SC and LIII nodal beds were contoured, and four treatment plans for each patient were generated. Three of the plans used empiric dose prescriptions, and these were compared with a CT-optimized plan. Each plan was evaluated by two criteria: whether 98% of target volume receive >90% of prescribed dose and whether < 5% of the irradiated volume received 105% of prescribed dose. RESULTS: The mean depth of SC and LIII were 3.2 cm (range, 1.4-6.7 cm) and 3.1 (range, 1.7-5.8 cm). The depth of these targets varied according across BMI classes (p = 0.01). Among the four sets of plans, the CT-optimized plans were the most successful at achieving both of the dosimetry objectives for every BMI class (normal BMI, p = .003; overweight BMI, p < .0001; obese BMI, p < .001). CONCLUSIONS: Across all BMI classes, routine radiation prescriptions did not optimally cover intended targets for every patient. Optimized CT-based treatment planning generated the most successful plans; therefore, we recommend the use of routine CT simulation and treatment planning of SC fields in breast cancer.
BACKGROUND: The purpose of this study was to determine whether the use of optimized CT treatment planning offered better coverage of axillary level III (LIII)/supraclavicular (SC) targets than the empirically derived dose prescription that are commonly used. MATERIALS/ METHODS: Thirty-two consecutive breast cancerpatients who underwent CT treatment planning of a SC field were evaluated. Each patient was categorized according to body mass index (BMI) classes: normal, overweight, or obese. The SC and LIII nodal beds were contoured, and four treatment plans for each patient were generated. Three of the plans used empiric dose prescriptions, and these were compared with a CT-optimized plan. Each plan was evaluated by two criteria: whether 98% of target volume receive >90% of prescribed dose and whether < 5% of the irradiated volume received 105% of prescribed dose. RESULTS: The mean depth of SC and LIII were 3.2 cm (range, 1.4-6.7 cm) and 3.1 (range, 1.7-5.8 cm). The depth of these targets varied according across BMI classes (p = 0.01). Among the four sets of plans, the CT-optimized plans were the most successful at achieving both of the dosimetry objectives for every BMI class (normal BMI, p = .003; overweight BMI, p < .0001; obese BMI, p < .001). CONCLUSIONS: Across all BMI classes, routine radiation prescriptions did not optimally cover intended targets for every patient. Optimized CT-based treatment planning generated the most successful plans; therefore, we recommend the use of routine CT simulation and treatment planning of SC fields in breast cancer.
Authors: Editha A Krueger; Benedick A Fraass; Daniel L McShan; Robin Marsh; Lori J Pierce Journal: Int J Radiat Oncol Biol Phys Date: 2003-07-15 Impact factor: 7.038
Authors: Lori J Pierce; Jennifer Moughan; Julia White; David P Winchester; Jean Owen; J Frank Wilson Journal: Int J Radiat Oncol Biol Phys Date: 2005-05-01 Impact factor: 7.038
Authors: Julia White; Jennifer Moughan; Lori J Pierce; Monica Morrow; Jean Owen; J Frank Wilson Journal: Int J Radiat Oncol Biol Phys Date: 2004-09-01 Impact factor: 7.038
Authors: Carolyn Taylor; Candace Correa; Frances K Duane; Marianne C Aznar; Stewart J Anderson; Jonas Bergh; David Dodwell; Marianne Ewertz; Richard Gray; Reshma Jagsi; Lori Pierce; Kathleen I Pritchard; Sandra Swain; Zhe Wang; Yaochen Wang; Tim Whelan; Richard Peto; Paul McGale Journal: J Clin Oncol Date: 2017-03-20 Impact factor: 44.544
Authors: Vicky Koh; Johann I Tang; Bok Ai Choo; Chek Wee Tan; Boon Keat Lim; Liang Shen; Jiade Jay Lu Journal: Onco Targets Ther Date: 2013-11-21 Impact factor: 4.147